RxDoctor Payments DataLook up a doctor →

Melvin Yee, MD

Neurology · Honolulu, HINPI 1124026455

Payments from drug & device makers

$31,629in general payments, 2019–2025

Across 1,190 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • UCB, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Avion Pharmaceuticals$2K
  • Acorda Therapeutics, Inc$2K
  • Medtronic$1K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$3,30510%
  • Speaking & faculty fees$1,8786%
  • Travel & lodging$1,0873%
  • Food & beverage$24,80778%
  • Education$5532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)177$5,778
UCB, Inc.104$2,683
Teva Pharmaceuticals USA, Inc.118$2,239
Avion Pharmaceuticals1$1,760
Acorda Therapeutics, Inc18$1,559
Medtronic(2 entities)11$1,498
AstraZeneca41$1,136
Amgen(2 entities)42$1,070
Neurocrine Biosciences, Inc.35$990
Jazz Pharmaceuticals Inc.26$961
Pfizer65$838
Sunovion Pharmaceuticals Inc.72$819
Eisai Inc.32$785
Lundbeck LLC34$767
Biogen33$726
Harmony Biosciences LLC24$706
SK Life Science, Inc.32$614
Argenx US, Inc.22$501
Neurelis, Inc.27$464
Tanabe Pharma America, Inc.22$442
Novartis23$426
Acadia Pharmaceuticals Inc20$421
Amneal Pharmaceuticals LLC20$382
CSL Behring16$323
EMD Serono, Inc.12$311
Biohaven Pharmaceutical Holding Company Ltd.19$265
Kyowa Kirin, Inc.13$247
Otsuka America Pharmaceutical, Inc.10$236
Upsher-smith Laboratories LLC11$209
Takeda Pharmaceuticals U.S.A., Inc.7$183
TG Therapeutics, Inc.7$177
Alnylam Pharmaceuticals Inc.7$172
Adamas Pharmaceuticals, Inc.7$149
Bristol Myers Squibb7$138
Grifols USA, LLC6$130
Biohaven Pharmaceuticals, Inc.6$117
Vanda Pharmaceuticals Inc.3$105
Sanofi4$101
Lilly USA, LLC4$100
Avanir Pharmaceuticals, Inc.4$82
Livanova USA, Inc.4$79
Otsuka Pharmaceutical Development & Commercialization, Inc.3$77
Catalyst Pharmaceuticals, Inc.3$74
Kowa Pharmaceuticals America, Inc.4$71
Genentech, Inc.3$67
Arbor Pharmaceuticals, Inc.4$65
Akcea Therapeutics, Inc.2$56
Axsome Therapeutics, Inc.2$54
Supernus Pharmaceuticals, Inc.3$54
Merz Pharmaceuticals, LLC2$52
Genentech USA, Inc.3$50
Mallinckrodt Hospital Products Inc.2$46
Merz North America, Inc.2$45
Insightec,inc2$44
Sarepta Therapeutics, Inc.2$43
Greenwich Biosciences, Inc.2$40
Amarin Pharma, Inc.2$37
Amylyx Pharmaceuticals, Inc.1$24
Impel Pharmaceuticals Inc.1$22
Cala Health, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,629 in reported general payments places this provider in the 85th percentile of 54 neurology providers in Hawaii.

See all neurology providers in Hawaii

Medicare billing

Part B allowed, 2024
$148,827
Medicare patients
520
Services billed
5,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab55$839,044
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$259,208
XywavSodium,calcium,mag,pot Oxybate12$237,389
RebifInterferon Beta-1a/Albumin11$134,700
NuplazidPimavanserin Tartrate22$110,762
AustedoDeutetrabenazine13$110,463
Nurtec OdtRimegepant Sulfate46$99,633
CopaxoneGlatiramer Acetate11$76,998
NeuproRotigotine22$37,734
Aimovig AutoinjectorErenumab-Aooe19$24,481
Carbidopa-LevodopaCarbidopa/Levodopa445$18,161
BotoxOnabotulinumtoxina12$15,140
BrilintaTicagrelor12$11,866
Memantine Hcl ErMemantine Hcl108$10,666
Ajovy SyringeFremanezumab-Vfrm14$10,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$501$839,04455 claims
CSL BehringHizentra$323$259,20813 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$2,239$187,46124 claims
EMD Serono, Inc.Rebif$311$134,70011 claims
Acadia Pharmaceuticals IncNuplazid$421$110,76222 claims
PfizerNurtec Odt$838$99,63346 claims
UCB, Inc.Neupro$2,683$37,73422 claims
AbbVieBotox$5,778$15,14012 claims
AstraZenecaBrilinta$1,136$11,86612 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$382$6,86452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 54 neurology providers in Hawaii.

Other neurology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →